Boston Scientific Corp is expected to report Q1 2026 revenue of $5.19 billion and adjusted EPS of $0.80, while its stock currently trades around $61.32 against an average analyst price target of $104.47.
Investors are primarily focused on the performance of the Electrophysiology segment, particularly the commercial adoption and competitive dynamics of the Farapulse Pulsed Field Ablation system.
Recent sentiment has been cautious following a Q4 revenue miss in the electrophysiology division, which triggered concerns about intensifying competition from rival technologies. However, strong momentum in the WATCHMAN franchise and the broader cardiovascular portfolio continues to underpin expectations for double-digit organic growth throughout the fiscal year.